The right question is never "which particle." It is "what is actually broken."
A pharmaceutical team has a drug that works. Potent compound, clean mechanism, compelling preclinical data. The problem is not the drug — it is getting it into a patient. The only solvent that dissolves it triggers rigors, hypotension, bronchospasm. Every infusion needs premedication and a nurse standing by with epinephrine. They reach for a nanoparticle. They spend a year on a liposome. They get nothing. What they missed: they applied a solution to a problem they did not have. This chapter teaches the diagnostic move before the engineering one.
Each platform was built to fix a specific failure mode. Matching one to another failure mode wastes a year — or ends a program.
Nanocarrier platforms are not ranked from worst to best. They are tools — each built to address a specific failure mode of drug delivery. The drugs that need carriers fail in different ways: some are insoluble, some are acutely toxic to a normal organ, some degrade before arrival, some need precise stoichiometry with a second drug. Each failure mode is a different engineering problem. Platform selection is a diagnostic exercise before it is an engineering one. State what is actually broken, then match it to what each platform mechanism actually addresses.
One architecture, two compartments. A liposome can carry either chemistry — but loading capacity and leakage are real constraints.
A liposome is a spherical vesicle — a bubble formed by a lipid bilayer. The same two-layer phospholipid arrangement that makes a cell membrane, curved into a closed sphere, enclosing a water-filled interior. This creates a two-compartment carrier: the aqueous core holds water-soluble drugs; the oily interior of the bilayer holds fat-soluble ones. A single platform that can, in principle, carry either chemistry. That versatility is real, but so are the constraints — hydrophobic drugs lodge in the bilayer where loading capacity is limited and leakage is a concern.
Three approved liposomal cancer drugs, and they tell the same story three different ways. Doxil reduces cardiac toxicity. Onivyde reduces acute gastrointestinal toxicity from irinotecan. And Vyxeos does something genuinely different: it encapsulates daunorubicin and cytarabine together in a fixed one-to-five molar ratio, so both drugs reach leukemia cells at the same time in the proportion that kills them most effectively. Vyxeos is the rare case where the nanocarrier provides an efficacy advantage beyond formulation — the fixed ratio matters biologically, and maintaining it during delivery is something only a co-encapsulated particle can do. Three approved liposomal cancer drugs: toxicity reduction, toxicity reduction, fixed-ratio efficacy. The EPR story is background to all of them.
The polymer chemistry is the release profile. But manufacturing at scale is the gating constraint — many beautiful preclinical PLGA programs never became drugs.
Polymeric nanoparticles are a fundamentally different architecture: a solid or semi-solid matrix of synthetic polymer with drug dispersed throughout. The dominant biodegradable polymer is PLGA — poly lactic-co-glycolic acid. It degrades by hydrolysis into lactic and glycolic acid, both naturally occurring metabolites. The degradation rate, and therefore the release rate, can be tuned by adjusting the ratio of lactic to glycolic acid and the polymer's molecular weight. Higher glycolic acid content degrades faster; higher molecular weight degrades slower. This tunability is the platform's signature feature. But the clinical footprint of PLGA in oncology is less prominent than liposomes despite decades of research — because manufacturing at scale is the gating constraint. Consistent particle size, drug loading, and surface properties at kilogram scale are not guaranteed from milligram-scale results.
That capacity expansion has direct implications for RNA-based cancer therapies and gene editing — a delivery platform matured by a pandemic.
Polymeric platforms also include lipid nanoparticles — a hybrid architecture sharing structural features with both liposomes and solid polymeric particles. Lipid nanoparticles became the delivery vehicle for the mRNA COVID-19 vaccines, which required stable encapsulation of fragile RNA payloads and efficient delivery into cells. The manufacturing scale-up driven by the pandemic dramatically expanded global capacity for lipid nanoparticle production. That expansion has direct implications for RNA-based cancer therapies and gene editing applications. A platform that existed before the pandemic has emerged from it with a global manufacturing infrastructure — an accelerant for RNA oncology that the field did not plan but is now inheriting.
By now a pattern has emerged, and it is worth making explicit. When a nanocarrier helps a patient, the benefit comes from one of three places. Reduced toxicity: the particle keeps drug away from healthy tissue that would otherwise be damaged — Doxil and the heart, Onivyde and the gut. Improved efficacy: the particle gets more active drug to the tumor or coordinates a combination that free drug cannot replicate — Vyxeos and its fixed ratio. Better formulation: the particle fixes a delivery problem that has nothing to do with tumor biology — Abraxane and Cremophor. These are not equivalent. Conflating them produces bad platform choices. The decision framework is diagnostic: state the drug's defects first, then match them to what each platform mechanism actually addresses.
The decision framework is a diagnostic tree, not a ranking. High lipophilicity with no organ-specific toxicity means a solubility problem, not an EPR problem — route to albumin or polymeric matrix. High organ-specific toxicity with acceptable formulation means a protection problem, not a solubility problem — route to a liposome with long circulation and controlled release. Sustained slow release of a hydrophobic compound is a kinetic problem — route to a PLGA matrix with tuned degradation. Co-delivery of two drugs at a fixed ratio is a stoichiometry problem — route to a co-encapsulating liposome. A drug's water solubility is often the first filter applied to platform selection, not the last. The drug's chemistry constrains the choice before the biology does.
Still open: whether EPR is reliable enough to remain a primary design target — and whether EPR-independent mechanisms alone justify continued nanocarrier development.
A platform that solves the therapeutic problem on paper but cannot be made reliably at scale is not a solution. Manufacturing is the constraint that filters everything, and students trained primarily on bench-scale pharmacology often underweight it. All three platforms add complexity over a small-molecule drug: liposomes need consistent particle size, bilayer lamellarity, drug-to-lipid ratio, and PEG surface density; polymeric particles need consistent polymer molecular weight, particle size, and drug loading; albumin particles need controlled aggregation and drug binding under shear. Abraxane succeeded partly because high-pressure homogenization is straightforward and scalable. Many beautiful PLGA programs never reached patients. The platform may have been matched to the problem. The manufacturing may not have been matched to the platform.
Cancer Nanomedicine · Chapter 3 · Nanocarrier Platforms
That is the chapter's only lesson, and it is a practical one. The most sophisticated particle is rarely the right answer. The right answer is the one matched to what is actually broken. Before asking which particle, ask what is wrong. If the drug lacks a toxic solvent problem, a liposome solves nothing. If the drug lacks organ toxicity, albumin protects nothing. If the release kinetics are not the issue, tuning a polymer degradation rate misses the point. Diagnose first. Then build the particle. And when you build it, build it as something that can be manufactured consistently — because a drug that exists only in a milligram-scale batch has not reached a patient.